Schizophrenia News

Published results showed patients with a mental health diagnosis who undergo surgery for bone or soft tissue sarcoma may be at risk for longer hospital stays, readmission and surgical site infection.

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.

NEW YORK — The prevalence of substance use disorders is high among patients with schizophrenia, Randall F. White, MD, said in this Healio Video Perspective from the American Psychiatric Association Annual Meeting.

NEW YORK — Gynecological conditions with hormonal derangements may contribute to secondary psychosis among adolescent females, according to results of a literature review presented at the American Psychiatric Association Annual Meeting.

NEW YORK — May is Mental Health Awareness Month, a perfect opportunity for individuals to focus on their state of mind, Carol A. Bernstein, MD, said in this Healio video from the American Psychiatric Association annual meeting.

Newron Pharmaceuticals announced positive topline results from its phase 2/3 study of evenamide for patients with chronic schizophrenia who have an inadequate response to current treatment with a second-generation antipsychotic.

Teva Pharmaceuticals and Medincell have announced positive efficacy results from the phase 3 SOLARIS clinical trial evaluating an investigational, monthly subcutaneous injectable in adults with schizophrenia.

NEW YORK — Lithium exposure in drinking water was associated with potentially detrimental effects on human health, including increased risk for autism spectrum disorder and schizophrenia spectrum disorder, according to researchers.

Results of a small pilot study suggest that the ketogenic diet may help counter adverse metabolic effects of psychotropic medications and improve mental health among adults with schizophrenia or bipolar disorder.

A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.